

Glossary A-Z

Orale Wirkstoffe Z

Zanubrutinib - BRUKINSA (USA)
[Navigation überspringen](#)

According to the NCI website **zanubrutinib** is an inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, zanubrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways, which leads to the inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B-lymphocyte development, activation, signaling, proliferation and survival. Check for [active clinical trials](#) using this agent.

[According to the Company BeiGene website](#)

BRUKINSA IS NOW APPROVED FOR ADULT PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY

More Information in English:

[Link to Drug Information Portal, a service of the U.S. National Library of Medicine, National Institutes of Health](#)

[Link to MedlinePlus, a service of the U.S. National Library of Medicine, National Institutes of Health](#)

[Link to National Cancer Institute](#)

[Wiki](#)

Link zu PharmaWiki

[Link to Physicians Desk Reference \(PDR\)](#)

[Link to European Medicines Agency \(EMA\)](#)

[Info for Patients presented by Scott Hamilton from Chemocare.com](#)

[Bruton's tyrosine kinase](#)